Dimensional Fund Advisors LP Has $231.59 Million Stake in ResMed Inc. $RMD

Dimensional Fund Advisors LP grew its position in ResMed Inc. (NYSE:RMD) by 6.2% in the third quarter, HoldingsChannel.com reports. The fund owned 846,134 shares of the medical equipment provider’s stock after buying an additional 49,540 shares during the quarter. Dimensional Fund Advisors LP’s holdings in ResMed were worth $231,587,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of RMD. SJS Investment Consulting Inc. increased its holdings in ResMed by 1,433.3% during the 3rd quarter. SJS Investment Consulting Inc. now owns 92 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 86 shares in the last quarter. WFA of San Diego LLC acquired a new position in ResMed in the second quarter worth $26,000. Westside Investment Management Inc. grew its holdings in shares of ResMed by 100.0% during the third quarter. Westside Investment Management Inc. now owns 132 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 66 shares during the last quarter. GoalVest Advisory LLC bought a new stake in shares of ResMed during the third quarter worth $37,000. Finally, IMA Advisory Services Inc. increased its stake in shares of ResMed by 52.7% in the third quarter. IMA Advisory Services Inc. now owns 139 shares of the medical equipment provider’s stock valued at $38,000 after buying an additional 48 shares in the last quarter. 54.98% of the stock is currently owned by institutional investors.

Insider Activity at ResMed

In other ResMed news, CEO Michael J. Farrell sold 4,991 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $273.78, for a total value of $1,366,435.98. Following the transaction, the chief executive officer directly owned 466,223 shares of the company’s stock, valued at approximately $127,642,532.94. This trade represents a 1.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Peter C. Farrell sold 2,000 shares of ResMed stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $260.22, for a total transaction of $520,440.00. Following the sale, the director directly owned 62,773 shares of the company’s stock, valued at $16,334,790.06. This represents a 3.09% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 16,082 shares of company stock worth $4,152,307 over the last 90 days. 0.65% of the stock is currently owned by company insiders.

ResMed Price Performance

Shares of RMD stock opened at $252.95 on Friday. The stock has a 50-day moving average price of $255.22 and a 200 day moving average price of $260.03. The company has a quick ratio of 2.32, a current ratio of 3.06 and a debt-to-equity ratio of 0.06. The firm has a market cap of $36.85 billion, a price-to-earnings ratio of 25.02, a PEG ratio of 1.68 and a beta of 0.88. ResMed Inc. has a 12 month low of $199.92 and a 12 month high of $293.81.

ResMed (NYSE:RMD) last released its earnings results on Thursday, January 29th. The medical equipment provider reported $2.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.68 by $0.13. The company had revenue of $1.42 billion for the quarter, compared to the consensus estimate of $1.40 billion. ResMed had a net margin of 27.53% and a return on equity of 25.20%. The company’s revenue was up 11.0% compared to the same quarter last year. During the same period in the prior year, the company posted $2.43 EPS. Research analysts expect that ResMed Inc. will post 9.47 EPS for the current year.

ResMed Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 19th. Investors of record on Thursday, February 12th will be issued a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 0.9%. The ex-dividend date is Thursday, February 12th. ResMed’s dividend payout ratio is currently 23.74%.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Robert W. Baird set a $281.00 price target on ResMed in a report on Friday, January 30th. Wall Street Zen upgraded shares of ResMed from a “hold” rating to a “buy” rating in a research report on Saturday, February 7th. Royal Bank Of Canada boosted their target price on shares of ResMed from $311.00 to $314.00 and gave the stock an “outperform” rating in a research note on Friday, January 30th. Citigroup upped their target price on shares of ResMed from $330.00 to $345.00 and gave the stock a “buy” rating in a research report on Monday, February 2nd. Finally, Weiss Ratings raised shares of ResMed from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Monday, February 9th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, ResMed currently has a consensus rating of “Moderate Buy” and an average price target of $299.27.

ResMed Profile

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.